The trial of PLX4032 offers a glimpse at how doctors, patients and drug developers navigate a medical frontier as more drugs tailored to the genetic profile of a cancer are being widely tested on humans for the first time.
Miracle?
Premise 1. Patient has weeks to live due to metastasized melanoma.
Premise 2. PLX4032 is administered at maximum dosage (for as little as two weeks) and immediate cancer remission takes place.
Conclusion: The cure for cancer is based in genetically tailored drug recipes.
FULL ARTICLE:
http://www.nytimes.com/2010/02/23/health/research/23trial.html
No comments:
Post a Comment